Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.33 |
| ▸ | F13A1 | P00488 | 1/20 | 0.32 |
| ▸ | TGM2 | P21980 | 1/20 | 0.32 |
| ▸ | TGM1 | P22735 | 1/20 | 0.32 |
| ▸ | TPSAB1 | Q15661 | 10/20 | 0.32 |
| ▸ | TPSD1 | Q9BZJ3 | 10/20 | 0.32 |
| ▸ | TPSG1 | Q9NRR2 | 10/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12166163 | 0.85 | EPHX1 (0.40) | EPHX1PDE4B | |
| SCHEMBL12166164 | 0.83 | PDE4B (0.34) | HSD11B1PDE4B | |
| SCHEMBL12166177 | 0.82 | PIK3CD (0.35) | — | |
| SCHEMBL12166174 | 0.81 | SMN1; SMN2 (0.44) | SMN1; SMN2 | |
| SCHEMBL12166167 | 0.81 | BCL9 (0.32) | TPSAB1TPSD1TPSG1 | |
| SCHEMBL12166179 | 0.78 | EPHX2 (0.37) | EPHX1SMN1; SMN2 | |
| SCHEMBL12166165 | 0.78 | JAK1 (0.33) | — | |
| SCHEMBL12166158 | 0.77 | EPHX1 (0.44) | EPHX1NPC1HTTRAB9ASMN1; SMN2 | |
| SCHEMBL12166182 | 0.77 | LMNA (0.35) | SMN1; SMN2 | |
| SCHEMBL12166178 | 0.77 | SMN1; SMN2 (0.45) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8361994-B2 | Primary amine diazeniumdiolate heterocyclic derivatives | MERCK SHARP & DOHME CORP (US) | 2013-01-29 | — | — | US | disclosed |
| US-20120232039-A1 | PRIMARY AMINE DIAZENIUMDIOLATE HETEROCYCLIC DERIVATIVES | MERCK SHARP & DOHME LLC | 2012-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232039-A1 | PRIMARY AMINE DIAZENIUMDIOLATE HETEROCYCLIC DERIVATIVES | EDNRA, PAH, EDNRB | EPHX1 110/4885F13A1 1939/4885TGM2 2394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.